Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association’s® (ADA) 85th Scientific Sessions in Chicago, U.S. from June 20 -23. Innovent will orally present the first Phase 3 study of mazdutide in Chinese adults with T2D (DREAMS-1). In addition, multiple exploratory MoA analyses of mazdutide as well as preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased in poster presentations. Details are listed below：
Title: Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1)
Abstract #：306-OR
Presentation Form: Oral presentation
Time: 2025 June 23, 14:15 PM – 14:30 PM（CST）
Presenter: Dr. Lei Qian, Innovent Biologics
Title: A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical study
Abstract #：1886-LB
Presentation Form: Poster presentation
Time: 2025 June 22, 12:30 PM – 1:30 PM（CST）
Presenter: Dr. Decheng Ren, Innovent Biologics
Title: The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat Accumulation
Abstract #：777-P
Presentation Form: Poster presentation
Time: 2025 June 22, 12:30 PM – 1:30 PM（CST）
Presenter: Dr.Tianpei Hong, Peking University Third Hospital
Title: Effect of Mazdutide on MASH Fibrosis – Targeting the Liver-Gut Axis and Microbiome
Abstract #：1616-P
Presentation Form: Poster presentation
Time: 2025 June 22, 12:30 PM – 1:30 PM（CST）
Presenter: Professor Ling Li, Zhongda Hospital Affiliated to Southeast University
Title: Mazdutide, a Dual GLP-1R/GCGRR Agonist, Reduces Hyperuricemia by Modulating Energy and Lipid Metabolism and Inhibiting Hepatic Purine Metabolism
Abstract #：775-P
Presentation Form: Poster presentation
Time: 2025 June 22, 12:30 PM – 1:30 PM（CST）
Presenter: Professor Hongwei Jiang, The First Affiliated Hospital of Henan University of Science and Technology
Dr. Lei Qian, Vice President of Clinical Development of Innovent, stated, “We are honored to orally present the results of mazdutide’s first Phase 3 clinical trial in T2D (DREAMS-1) at the ADA Scientific Sessions. We are also delighted to see mazdutide’s mechanism exploration studies featured extensively at the conference. The growing body of medical evidence will further validate mazdutide’s differentiated profile as a next-generation GCG/GLP-1 dual receptor agonist, in particularly in liver fat and serum urine reduction. Moreover, in the field of cardiovascular and metabolic diseases, Innovent is dedicated to developing next-generation innovative therapies, including IBI3030（PCSK9-GGG）with novel modality and MoA, to meaningfully improve outcomes for more patients worldwide.”
